Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study

Abstract

In treatment-naive/-experienced HCV-1/HIV-1 patients there were significantly higher SVR rates with telaprevir-based therapy compared with pre-specified historical controls, and safety comparable to that in HCV-monoinfected patients.

The Significance of Type-I Interferons in the Pathogenesis and Therapy of Human Immunodeficiency Virus 1 Infection

“…At the same time, IFN-α was added to current treatment of cART, but the results seemed paradoxical: one indicated that IFN-α had a negative effect on disease progression ( 133 ), while the other suggested IFN-α decreased HIV reservoirs and delayed virus rebound after treatment interruption ( 134 ). Recently, two researches recruited patients who was coinfected with HIV/HCV and received IFN-α in combination with ribavirin, the result of which showed a reduction in integrated HIV-DNA and 2-LTR circular HIV-DNA ( 135 – 137 ). Altogether, administration of exogenous IFN-α intends to decrease HIV-RNA or HIV-DNA transiently in these studies.…”

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

“…However, data on the efficacy of this regimen in patients who have not responded to previous PEG-IFN/RBV therapy are scarce. [12][13][14][15][16][17] Although triple therapy achieves higher rates of SVR than conventional therapies, it may be more toxic and is clearly more expensive. There are data indicating that response-guided therapy (RGT) (32 weeks of triple therapy) in HCV monoinfected patients with previous failure to PEG-IFN/RBV therapy can be as effective as the standard triple therapy (44 weeks), but with lower toxicity and cost.…”